Discontinued — last reported Q2 '18
Other
Fair Value Measurement Disclosure
Amgen Fair Value Measurement Disclosure decreased by 11.3% to $904.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 2.0%, from $886.00M to $904.00M.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryRisk
SignalContext dependent
VolatilityVolatile
First reportedQ3 2015
Last reportedQ2 2018
How to read this metric
Higher levels indicate a larger portion of the balance sheet is subject to market-based valuation volatility.
Detailed definition
This represents the aggregate carrying amount of assets and liabilities that are measured at fair value on a recurring o...
Peer comparison
Standard disclosure for financial institutions with significant investment holdings.
Metric ID:
fair_value_measurement_disclosureHistorical Data
8 periods
| Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|
| Value | $145.00M | $1.07B | $1.03B | $886.00M | $420.00M | $880.00M | $1.02B | $904.00M |
| QoQ Change | — | +639.3% | -4.2% | -13.7% | -52.6% | +109.5% | +15.8% | -11.3% |
| YoY Change | — | — | — | — | +189.7% | -17.9% | -0.8% | +2.0% |
Range$145.00M – $1.07B
CAGR+184.6%
Avg YoY Growth+43.2%
Median YoY Growth+0.6%
Fair Value Measurement Disclosure at Other Companies
Frequently Asked Questions
- What is Amgen's fair value measurement disclosure?
- Amgen (AMGN) reported fair value measurement disclosure of $904.00M in Q3 2025.
- How has Amgen's fair value measurement disclosure changed year-over-year?
- Amgen's fair value measurement disclosure increased by 2.0% year-over-year, from $886.00M to $904.00M.
- What does fair value measurement disclosure mean?
- The total value of assets and liabilities reported at current market prices.